U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2017
422
Name Type Language
AVELUMAB
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
AVELUMAB [USAN]
Common Name English
MSB0010682
Code English
AVELUMAB [MI]
Common Name English
avelumab [INN]
Common Name English
MSB0010718C
Common Name English
BAVENCIO
Brand Name English
Avelumab [WHO-DD]
Common Name English
MSB-0010682
Code English
IMMUNOGLOBULIN G1-LAMBDA1, ANTI-(HOMO SAPIENS CD274 (PROGRAMMED DEATH LIGAND 1, PDL1, PD-L1, B7 HOMOLOG 1, B7H1)), HOMO SAPIENS MONOCLONAL ANTIBODY
Common Name English
AVELUMAB [JAN]
Common Name English
AVELUMAB [PURPLE BOOK CDER]
Common Name English
MSB-0010718C
Common Name English
Classification Tree Code System Code
WHO-ATC L01XC31
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
NCI_THESAURUS C128057
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
FDA ORPHAN DRUG 491815
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
NDF-RT N0000193338
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
FDA ORPHAN DRUG 604117
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
EU-Orphan Drug EU/3/15/1590
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
Code System Code Type Description
DAILYMED
KXG2PJ551I
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
DRUG CENTRAL
5221
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
SMS_ID
100000166075
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
EVMPD
SUB180078
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
USAN
DE-160
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
RXCUI
1875534
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
CAS
1537032-82-8
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
DRUG BANK
DB11945
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
NCI_THESAURUS
C116870
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
FDA UNII
KXG2PJ551I
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
WIKIPEDIA
Avelumab
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
MERCK INDEX
m11986
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
INN
10062
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
LACTMED
Avelumab
Created by admin on Sat Dec 16 17:56:09 UTC 2023 , Edited by admin on Sat Dec 16 17:56:09 UTC 2023
PRIMARY
ACTIVE MOIETY
AVELUMAB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966